Lee JL - Search Results

1

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators. Bellmunt J, et al. Among authors: lee jl. N Engl J Med. 2017 Mar 16;376(11):1015-1026. doi: 10.1056/NEJMoa1613683. Epub 2017 Feb 17. N Engl J Med. 2017. PMID: 28212060 Free PMC article. Clinical Trial.

2

Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.

Lee SS, Lee JL, Ryu MH, Chang HM, Kim TW, Kang HJ, Kim WK, Lee JS, Kang YK. Lee SS, et al. Among authors: lee js, lee jl. Jpn J Clin Oncol. 2007 Jan;37(1):30-7. doi: 10.1093/jjco/hyl134. Jpn J Clin Oncol. 2007. PMID: 17272321

3

Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis.

Jo JC, Lee JL, Ryu MH, Sym SJ, Lee SS, Chang HM, Kim TW, Lee JS, Kang YK. Jo JC, et al. Among authors: lee js, lee ss, lee jl. Jpn J Clin Oncol. 2007 Dec;37(12):936-41. doi: 10.1093/jjco/hym123. Jpn J Clin Oncol. 2007. PMID: 18211985

4

A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.

Kim C, Lee JL, Ryu MH, Chang HM, Kim TW, Lim HY, Kang HJ, Park YS, Ryoo BY, Kang YK. Kim C, et al. Among authors: lee jl. Invest New Drugs. 2011 Apr;29(2):366-73. doi: 10.1007/s10637-009-9363-0. Epub 2009 Dec 9. Invest New Drugs. 2011. PMID: 19997960 Clinical Trial.

5

Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer.

Kim C, Lee JL, Choi YH, Kang BW, Ryu MH, Chang HM, Kim TW, Kang YK. Kim C, et al. Among authors: lee jl. Invest New Drugs. 2012 Feb;30(1):306-15. doi: 10.1007/s10637-010-9531-2. Epub 2010 Sep 14. Invest New Drugs. 2012. PMID: 20839031 Clinical Trial.

6

Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.

Yoon DH, Ryu MH, Ryoo BY, Beck M, Choi DR, Cho Y, Lee JL, Chang HM, Kim TW, Kang YK. Yoon DH, et al. Among authors: lee jl. Invest New Drugs. 2012 Apr;30(2):819-27. doi: 10.1007/s10637-010-9593-1. Epub 2010 Nov 23. Invest New Drugs. 2012. PMID: 21104107

7

Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.

Kang MJ, Hong YS, Kim KP, Kim SY, Baek JY, Ryu MH, Lee JL, Chang HM, Kim MJ, Chang HJ, Kang YK, Kim TW. Kang MJ, et al. Among authors: lee jl. Invest New Drugs. 2012 Aug;30(4):1607-13. doi: 10.1007/s10637-011-9703-8. Epub 2011 Jun 25. Invest New Drugs. 2012. PMID: 21706149 Clinical Trial.

8

Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum.

Lee JL, Ahn JH, Park SH, Lim HY, Kwon JH, Ahn S, Song C, Hong JH, Kim CS, Ahn H. Lee JL, et al. Invest New Drugs. 2012 Oct;30(5):1984-90. doi: 10.1007/s10637-011-9757-7. Epub 2011 Oct 20. Invest New Drugs. 2012. PMID: 22012004 Clinical Trial.

9

Venous thromboembolism (VTE) in patients with advanced gastric cancer: an Asian experience.

Kang MJ, Ryoo BY, Ryu MH, Koo DH, Chang HM, Lee JL, Kim TW, Kang YK. Kang MJ, et al. Among authors: lee jl. Eur J Cancer. 2012 Mar;48(4):492-500. doi: 10.1016/j.ejca.2011.11.016. Epub 2011 Dec 12. Eur J Cancer. 2012. PMID: 22169121

10

Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy.

Hong YS, Lee J, Kim KP, Lee JL, Park YS, Park JO, Park SH, Kim SY, Baek JY, Kim JH, Lee KW, Kim TY, Kim TW. Hong YS, et al. Among authors: lee j, lee kw, lee jl. Invest New Drugs. 2013 Feb;31(1):183-91. doi: 10.1007/s10637-012-9853-3. Epub 2012 Jul 11. Invest New Drugs. 2013. PMID: 22782485 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,060 results

Search Page